Xenetic receives FDA approval to initiate Phase II trial of Virexxa to treat endometrial cancer

Biopharmaceutical company Xenetic has received the US Food and Drug Administration (FDA) approval of an investigational new drug (IND) application to begin the Phase II clinical trial of Virexxa for the treatment of endometrial cancer in women.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news